https://www.selleckchem.com/products/bai1.html
0221) among CML patients with chronic phase, but not with Transformation-free survival (TFS; = 0.0821). Furthermore, higher RDW was associated with higher mortality compared to patients with low RDW (CML-associated deaths; 0.0001). In addition, a decline in RDW is associated with the treatment of CML patients with tyrosine kinase inhibitors, especially at 6 and 12 months after the start of treatment. Higher RDW is a potential prognostic biomarker for chronic CML patients. Higher RDW is a potential prognostic biomarker for chronic CML
Like
Comment
Share
